These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 23764045)
21. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585 [TBL] [Abstract][Full Text] [Related]
22. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950 [TBL] [Abstract][Full Text] [Related]
23. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804 [TBL] [Abstract][Full Text] [Related]
25. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model. Zhu Z; Jiang W; McGinley JN; Thompson HJ Cancer Prev Res (Phila); 2013 Apr; 6(4):290-8. PubMed ID: 23365133 [TBL] [Abstract][Full Text] [Related]
26. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324 [TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo. Yang B; Yu D; Liu J; Yang K; Wu G; Liu H Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979 [TBL] [Abstract][Full Text] [Related]
29. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. Xu XD; Yang L; Zheng LY; Pan YY; Cao ZF; Zhang ZQ; Zhou QS; Yang B; Cao C BMC Cancer; 2014 May; 14():373. PubMed ID: 24886166 [TBL] [Abstract][Full Text] [Related]
30. Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors. Moreno N; Kerl K Anticancer Res; 2016 Aug; 36(8):3883-7. PubMed ID: 27466490 [TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Namdar M; Perez G; Ngo L; Marks PA Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108 [TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Dowdy SC; Jiang S; Zhou XC; Hou X; Jin F; Podratz KC; Jiang SW Mol Cancer Ther; 2006 Nov; 5(11):2767-76. PubMed ID: 17121923 [TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526 [TBL] [Abstract][Full Text] [Related]
34. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057 [TBL] [Abstract][Full Text] [Related]
35. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
36. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells. Liang BY; Xiong M; Ji GB; Zhang EL; Zhang ZY; Dong KS; Chen XP; Huang ZY J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):535-540. PubMed ID: 26223923 [TBL] [Abstract][Full Text] [Related]
37. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306 [TBL] [Abstract][Full Text] [Related]
38. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547 [TBL] [Abstract][Full Text] [Related]
39. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Staberg M; Michaelsen SR; Rasmussen RD; Villingshøj M; Poulsen HS; Hamerlik P Cell Oncol (Dordr); 2017 Feb; 40(1):21-32. PubMed ID: 27766591 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]